Editor's Pick

House GOP escalates war on Justice Dept. as members flock to Trump trial

The Republican chairs of the powerful House Judiciary and Oversight committees slammed the Biden administration this week, accusing the president and Attorney General Merrick Garland of politicizing the justice system.

But as Reps. Jim Jordan (R-Ohio) and James Comer (R-Ky.) pilloried the White House and the Justice Department, their committees were hobbled by attendance problems: At least five members were in New York on Thursday morning, standing behind former president Donald Trump at his criminal trial and inserting themselves, and their political views, into the same justice system the two chairmen claimed to be defending from politicization.

This post appeared first on The Washington Post

You May Also Like

Investing

2023 was a relatively lackluster year, silver largely traded on volatility between US$22 and US$25 per ounce. The white metal started 2024 with less...

Latest News

Dong’s experience, both as head of the People’s Liberation Army Navy (PLAN) as well as operational assignments in the Chinese military’s Eastern and Southern...

Investing

The US was one of the world’s top silver producers in 2023, recording output of 1,000 metric tons (MT). While that’s far below first-place...

Investing

The Canadian pharmaceutical market is the eighth largest in the world and accounts for 2.2 percent of the global prescription drug market. But what...

Disclaimer: GreatWallStreetPublisher.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 GreatWallStreetPublisher.com

Exit mobile version